1. A Population-Based Approach to Reporting System-Level Performance Measures for Rheumatoid Arthritis Care.
- Author
-
Barber CEH, Marshall DA, Szefer E, Barnabe C, Shiff NJ, Bykerk V, Homik J, Thorne JC, Ahluwalia V, Benseler S, Mosher D, Twilt M, and Lacaille D
- Subjects
- Adult, Aged, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid epidemiology, British Columbia epidemiology, Databases, Factual, Drug Utilization standards, Female, Humans, Incidence, Male, Middle Aged, Practice Patterns, Physicians' standards, Prevalence, Referral and Consultation standards, Rheumatologists standards, Time Factors, Time-to-Treatment standards, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Quality Indicators, Health Care standards, Rheumatology standards
- Abstract
Objective: To operationalize and report on nationally endorsed rheumatoid arthritis (RA) performance measures (PMs) using health administrative data for British Columbia (BC), Canada., Methods: All patients with RA in BC ages ≥18 years were identified between January 1, 1997 and December 31, 2009 using health administrative data and followed until December 2014. PMs tested include: the percentage of incident patients with ≥1 rheumatologist visit within 365 days; the percentage of prevalent patients with ≥1 rheumatologist visit per year; the percentage of prevalent patients dispensed disease-modifying antirheumatic drug (DMARD) therapy; and time from RA diagnosis to DMARD therapy. Measures were reported on patients seen by rheumatologists, and in the total population., Results: The cohort included 38,673 incident and 57,922 prevalent RA cases. The percentage of patients seen by a rheumatologist within 365 days increased over time (35% in 2000 to 65% in 2009), while the percentage of RA patients under the care of a rheumatologist seen yearly declined (79% in 2001 to 39% in 2014). The decline was due to decreasing visit rates with increasing follow-up time rather than calendar effect. The percentage of RA patients dispensed a DMARD was suboptimal over follow-up (37% in 2014) in the total population but higher (87%) in those under current rheumatologist care. The median time to DMARD in those seen by a rheumatologist improved from 49 days in 2000 to 23 days in 2009, with 34% receiving treatment within the 14-day benchmark., Conclusion: This study describes the operationalization and reporting of national PMs using administrative data and identifies gaps in care to further examine and address., (© 2020, American College of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF